Biostock interview: Chordate CEO Anders Weilandt on International specialist congress and upcoming milestones

Biostock interviews Chordate Medical’s CEO Anders Weilandt about the International Headache Congress in Seoul, where the results from the migraine study will be presented, and about the manuscript for a scientific article that has now been submitted.

“It is a much-awaited achievement that now, after thorough analysis and writing process by the authors, can be ticked off as delivered. The data material is extensive and in many parts very interesting. As I understand it, there has been some work in choosing what to include in this first article. It is not unlikely that further analysis may result in several articles on aspects other than those presented in this article. Overall, I am very pleased good that the article has been produced – it will provide good support for our marketing work when the article is approved for publication”, says Anders Weilandt to Biostock.

Read the full article

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy